Core Insights - IQVIA Holdings Analytics Inc. reported strong third-quarter 2024 results, with adjusted earnings of $2.8 per share, exceeding the Zacks Consensus Estimate by 1.1% and reflecting a year-over-year increase of 14.1% [1] - Total revenues reached $3.9 billion, surpassing the consensus estimate by 1.1% and growing 4.3% compared to the same quarter last year [1] Revenue Breakdown - The Research and Development segment generated revenues of $2.2 billion, a 1.9% increase year-over-year, meeting estimates [2] - Revenues from the Technology and Analytics segment were $1.6 billion, an 8.6% increase from Q3 2023, beating the estimate of $1.5 billion [3] - Contract Sales & Medical Solutions revenues decreased by 1.6% year-over-year to $180 million, missing expectations of $182.9 million [3] Financial Metrics - Adjusted EBITDA for Q3 2024 was $939 million, a 5.7% increase from the previous year, exceeding projections [4] - The company ended the quarter with cash and cash equivalents of $1.6 billion, up from $1.5 billion in the previous quarter, while long-term debt increased to $12.3 billion from $12.1 billion [4] Cash Flow and Capital Expenditure - Net cash generated from operating activities was $721 million, with capital expenditure at $150 million, resulting in a free cash flow of $571 million for the quarter [5] 2024 Guidance - IQVIA revised its 2024 revenue guidance to $15.35-$15.40 billion, down from the previous range of $15.43-$15.53 billion, with the Zacks Consensus Estimate at $15.46 billion [6] - Adjusted EPS guidance was updated to $11.10-$11.20, lower than the previous range and below the Zacks Consensus Estimate of $11.17 [7] - Adjusted EBITDA guidance was also reduced to $3.67-$3.70 billion from $3.71-$3.77 billion [7]

Exhibit 99.1 IQVIA Reports Third-Quarter 2024 Results and Announces Investor Day • Revenue of $3,896 million • GAAP Net Income of $285 million, Adjusted EBITDA of $939 million • GAAP Diluted Earnings per Share of $1.55, Adjusted Diluted Earnings per Share of $2.84 • R&D Solutions quarterly bookings of $2.3 billion, resulting in trailing-twelve-month bookings of $10.4 billion and a trailing-twelve-month book-to-bill ratio of 1.22x • R&D Solutions contracted backlog of $31.1 billion, up 8.0 percent reported y ...

IQVIA Holdings, Inc. (IQV) is scheduled to release its third-quarter 2024 results on Oct. 31, before market open. See Zacks Earnings Calendar to stay ahead of market-making news. IQV has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 1.8%. IQVIA's Q3 Expectations The Zacks Consensus Estimate for revenues is pegged at $3.9 billion, implying 3.1% growth from the year-ago quarter's actual. The top line is likely t ...

The market expects IQVIA Holdings (IQV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on October 31, 2024, might help the stock move higher if these key numbe ...

IQVIA Holdings Inc. (IQV) has had an impressive run over the past three months. The stock has gained 9.3%, outperforming the 3.9% rise of the industry it belongs to and the Zacks S&P 500 composite's 2% uptick. IQV has an expected long-term (three to five years) EPS growth rate of 10.4%. The company's earnings for 2024 and 2025 are expected to grow 9.6% and 10.6%, respectively. IQV's Global Reach, Market Leadership in Healthcare Analytics IQVIA operates in over 100 countries, giving it a vast global footprin ...

IQVIA Holdings Inc. (IQV) had an impressive run in the past three months. The company's shares have gained 12.5% compared with the 3.4% rally of its industry and the 2.5% rise of the Zacks S&P 500 composite. IQV reported impressive second-quarter 2024 results. Adjusted earnings (excluding 67 cents from nonrecurring items) were $2.6 per share, outpacing the Zacks Consensus Estimate by 2.3% and increasing 2.4% on a year-over-year basis. Total revenues of $3.8 billion surpassed the consensus estimate marginall ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What ...

PHILADELPHIA, Sept. 4, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today it has joined IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. IQVIA One Home for Sites is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solu ...

It has been about a month since the last earnings report for IQVIA Holdings (IQV) . Shares have added about 3.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is IQVIA due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. IQVIA Surpasses Q2 Earnings Estimates IQVIA Holdin ...